Results 211 to 220 of about 3,182,211 (266)
Prevalence of anti HCV antibodies and anti HBV antibodies is risk groups of patients
, 2018 Odalović Andrijana +4 more
openalex +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Hepatology, 2018
BACKGROUND & AIMS The efficacy of direct-acting antivirals (DAAs) has dramatically changed the prognosis of patients with chronic hepatitis C. We aimed to evaluate the impact of DAA therapy on the composition of the liver transplant (LT) waiting list and
G. Crespo +9 more
semanticscholar +1 more source
BACKGROUND & AIMS The efficacy of direct-acting antivirals (DAAs) has dramatically changed the prognosis of patients with chronic hepatitis C. We aimed to evaluate the impact of DAA therapy on the composition of the liver transplant (LT) waiting list and
G. Crespo +9 more
semanticscholar +1 more source
Evaluation systems for anti-HCV drugs
Advanced Drug Delivery Reviews, 2007Development of therapeutics for chronic hepatitis C has been hampered by the lack of an efficient cell culture system and a small animal model for the hepatitis C virus (HCV). An RNA replicon system, in which the HCV genome replicates autonomously in cells, and replication competent viruses derived from an HCV genotype 2a JFH1 strain efficiently ...
Kohji, Moriishi, Yoshiharu, Matsuura
openaire +2 more sources
Cyclosporine pharmacokinetics in anti‐HCV+ patients
Clinical Transplantation, 2004Abstract: Background: Cyclosporine (CsA) is a widely used immunosuppressive agent in kidney transplant patients. In Brazil, around 30% of patients awaiting kidney transplantation carry anti‐HCV antibodies. Previous observations suggest altered CsA pharmacokinetics in these patients.Methods: We conducted two pharmacokinetic studies.
Luciano, Wolffenbüttel +3 more
openaire +2 more sources
Resistance to anti-HCV protease inhibitors
Current Opinion in Virology, 2011The era of direct acting antiviral therapy for HCV infection has dawned with the recent approval of the NS3 protease inhibitors telaprevir and boceprevir. The development of DAA therapy is an exciting advance for clinicians and patients, but it will also bring new challenges.
Thompson, A.J. +2 more
openaire +3 more sources
The Specificity of Anti‐HCV Supplementary Assays
Vox Sanguinis, 1995AbstractA total of 920 samples from blood donors screened as anti‐HCV negative by two third‐generation screening assays (Ortho Diagnostics v3.0 and Murex Diagnostics VK48) were tested by two supplementary anti‐HCV assays, RIBA III (Ortho Diagnostics) and Western blot (Murex Diagnostics VK68).
A D, Kitchen, N V, Tucker
openaire +2 more sources
Second-Generation Anti-HCV Tests Predict Infectivity
Vox Sanguinis, 1992AbstractTwenty‐four blood donors found positive for the first‐generation hepatitis C antibody (anti‐HCV) test (Ortho EIA‐I) and 88 of their recipients over the period from 1972 to 1990 were retrospectively investigated with different first‐and second‐generation anti‐HCV tests.
J, Larsen, K, Skaug, A, Maeland
openaire +2 more sources
Clinica chimica acta; international journal of clinical chemistry, 2013
BACKGROUND Anti-HCV assays remain the first choice for screening HCV infection in most clinical laboratories. The Elecsys anti-HCV II assay has been recently launched and we aimed to evaluate its performance compared with other widely used methods ...
Rui‐feng Yang +4 more
semanticscholar +1 more source
BACKGROUND Anti-HCV assays remain the first choice for screening HCV infection in most clinical laboratories. The Elecsys anti-HCV II assay has been recently launched and we aimed to evaluate its performance compared with other widely used methods ...
Rui‐feng Yang +4 more
semanticscholar +1 more source
Discovery medicine, 2007
Hepatitis C virus (HCV) infects about 2% of the world population or approximately 123 million people. The disease causes a significant level of morbidity and mortality among those afflicted. The combination of interferon and ribavirin is effective in many patients.
Stanislas, Pol, Vincent O, Mallet
openaire +1 more source
Hepatitis C virus (HCV) infects about 2% of the world population or approximately 123 million people. The disease causes a significant level of morbidity and mortality among those afflicted. The combination of interferon and ribavirin is effective in many patients.
Stanislas, Pol, Vincent O, Mallet
openaire +1 more source